Overall survival of first‐line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study

類似資料

• Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study
  著者:: Tomita, Yoshihiko, 等
  出版事項: (2019)
• Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study
  著者:: Tomita, Yoshihiko, 等
  出版事項: (2016)
• Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma
  著者:: Eto, Masatoshi, 等
  出版事項: (2014)
• Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101
  著者:: Uemura, Motohide, 等
  出版事項: (2020)
• Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial
  著者:: Ioka, Tatsuya, 等
  出版事項: (2015)